Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.

Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, Baladandayuthapani V, Rice D, Sepesi B, Ji L, Roth JA.

Cancer Immunol Res. 2018 Feb;6(2):163-177. doi: 10.1158/2326-6066.CIR-17-0273. Epub 2018 Jan 16.

2.

The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.

Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD, Roth JA.

PLoS One. 2013 Oct 17;8(10):e77067. doi: 10.1371/journal.pone.0077067. eCollection 2013.

3.

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.

Adeegbe DO, Liu S, Hattersley MM, Bowden M, Zhou CW, Li S, Vlahos R, Grondine M, Dolgalev I, Ivanova EV, Quinn MM, Gao P, Hammerman PS, Bradner JE, Diehl JA, Rustgi AK, Bass AJ, Tsirigos A, Freeman GJ, Chen H, Wong KK.

Cancer Immunol Res. 2018 Oct;6(10):1234-1245. doi: 10.1158/2326-6066.CIR-18-0077. Epub 2018 Aug 7.

4.

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.

Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA.

PLoS One. 2015 Jun 8;10(6):e0123967. doi: 10.1371/journal.pone.0123967. eCollection 2015.

5.

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.

Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, Baladandayuthapani V, Song J, Fang B, Ji L, Mehran R, Roth JA.

Sci Rep. 2016 Nov 15;6:35741. doi: 10.1038/srep35741.

6.

Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.

Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, Zhou C.

J Thorac Oncol. 2017 Jul;12(7):1085-1097. doi: 10.1016/j.jtho.2017.04.014. Epub 2017 May 3.

7.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.

J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36.

8.

IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.

Seo H, Kim BS, Bae EA, Min BS, Han YD, Shin SJ, Kang CY.

Cancer Immunol Res. 2018 Jun;6(6):685-695. doi: 10.1158/2326-6066.CIR-17-0708. Epub 2018 Apr 3.

9.

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.

Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT.

Cancer Immunol Res. 2016 Jul;4(7):611-20. doi: 10.1158/2326-6066.CIR-15-0252. Epub 2016 Apr 13.

10.

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R.

Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.

11.

The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS.

J Thorac Oncol. 2019 Jun;14(6):1046-1060. doi: 10.1016/j.jtho.2019.02.004. Epub 2019 Feb 13.

12.

Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R.

Clin Cancer Res. 2017 Sep 1;23(17):5187-5201. doi: 10.1158/1078-0432.CCR-17-0741. Epub 2017 Jul 11.

13.

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Cancer Immunol Res. 2017 Sep;5(9):767-777. doi: 10.1158/2326-6066.CIR-16-0365. Epub 2017 Aug 17.

14.

Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.

Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S, Deshane JS.

Oncotarget. 2016 Nov 15;7(46):75407-75424. doi: 10.18632/oncotarget.12249.

15.

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549. doi: 10.1073/pnas.1714089115. Epub 2018 Jan 31.

17.

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.

Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P.

Cancer Immunol Immunother. 2019 Mar;68(3):379-393. doi: 10.1007/s00262-018-2283-0. Epub 2018 Dec 13.

PMID:
30547218
18.

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG.

Cancer Immunol Immunother. 2018 Mar;67(3):381-392. doi: 10.1007/s00262-017-2091-y. Epub 2017 Nov 9.

PMID:
29124315
19.

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA.

PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25.

20.

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.

Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. doi: 10.1158/1078-0432.CCR-16-2677. Epub 2017 Aug 28.

Supplemental Content

Support Center